Berkshire Hathaway (BRK-B) Valuation: Multiples vs History, DCF Fair Value and Analyst Targets

Company Valuation Highlights

Leverage Assessment

Portfolio-level leverage is moderate — the single holding (Berkshire B) is classified as 'Moderate' with Net Debt/EBITDA = 1.19x. The equity-heavy EV structure (market cap ~90.5% of EV) and $51.9B of cash provide a sizable liquidity buffer and low net financial risk relative to more indebted corporates. Actionable next steps: (1) run a DCF to test valuation against the report’s >15% upside/downside thresholds, (2) compare Berkshire’s EV/EBITDA and EV/Sales to direct conglomerate and insurance peers and to its own 5‑year averages, and (3) review the debt maturity schedule, effective interest rates, and insurance float dynamics to ensure the 'Moderate' classification remains appropriate under stress scenarios.

DCF Verdicts by Company

• Market Risk Premium: Calculated dynamically based on credit spreads. Formula: ERP = 3.0% + (BAA Spread - 1.5%). When spreads are tight, ERP is lower; when spreads widen, ERP increases.
• Terminal Growth Rate: Sector-based assumptions: Technology, Communication Services: 3.5% | Healthcare, Consumer Cyclical: 3.0% | Industrials, Financials, Consumer Defensive, Materials: 2.5% | Energy, Utilities, Real Estate: 2.0%
• Shares Outstanding: Adjusted for historical buyback trends when applicable.

BRK-B – Berkshire Hathaway Inc.

WACC Calculation

Historical Free Cash Flow

FCF CAGRs: 5Y: -1.3% | 10Y: 5.0% | Avg FCF Margin (5Y): 6.7%

DCF Valuation (Two Methods)

Sensitivity Analysis (Historical Method)

Intrinsic value per share varying WACC and Terminal Growth Rate

Current price: $492.27 | Highlighted row shows base case WACC (6.22%)

Price Target Trend Analysis

Analyst targets are effectively stable with no directional trend reported; the steady consensus target and the 'Hold' sentiment suggest analysts see BRK‑B as fairly valued or lacking clear catalysts. The consensus target sits below the market price (−5.4%), and the target range ($450–$481) is relatively narrow, indicating analytical agreement on a modest downside scenario. However, coverage is light (three analysts), so the absence of target movement could reflect low analyst engagement rather than strong conviction. Actionable next steps: investors should seek clarity on the assumptions driving the target — especially expectations for investment income and one‑time items — and confirm whether a firm DCF or scenario analysis supports the prevailing target range before changing position sizing.

P/E Trajectory Analysis

The rise in P/E from 15.9x (TTM) to 23.0x (forward) is not a sign of increased optimism about growth; it principally reflects lower forecasted EPS (forward EPS $21.43 vs implied trailing EPS ≈$30.96). A higher forward P/E in the face of falling EPS typically signals expected earnings weakness or the loss of prior one‑off gains. For investors this means: (a) validate the expected earnings decline — determine if it is temporary (non‑recurring items) or structural, and (b) adjust valuation methods accordingly. If a formal DCF (not provided here) yields an upside greater than 15%, that would argue the market/analysts are too pessimistic; conversely, a DCF downside greater than 15% would reinforce the view implied by the higher forward P/E. Given the magnitude of the EPS deterioration baked into the forward multiple, the priority is to reconcile accounting and investment income assumptions behind the forecasts before treating the current multiple profile as attractive.

Investment Implications

For value-oriented investors who prioritize earnings and cash flow, the multi‑method analysis argues for caution or a wait‑for‑entry approach. The median implied value ($346.09) and DCF ($360.47) indicate downside of roughly 26–30% from the current price; these are the most direct measures of intrinsic and operating performance and suggest the stock is overvalued at $492.27. The P/S result ($235.02) reinforces the view that revenue‑relative multiples do not support today’s price. That said, investors who prioritize balance‑sheet strength and long‑term optionality (insurance float, large equity portfolio, conservative capital allocation) may place more weight on the P/B outcome ($530.73). In that narrower, book‑value‑oriented view the stock looks reasonably priced or only modestly expensive. Wall Street’s consensus ($465.50) sits between these poles, implying limited near‑term upside in sell‑side estimates. Actionable guidance: avoid initiating a full position at current levels if your primary valuation anchor is earnings or cash flows; consider setting a target entry in the $340–$370 range aligned with the median and DCF results, or use phased purchases (dollar‑cost averaging) to limit timing risk. If you are a long‑term investor who values Berkshire’s capital allocation track record and balance sheet, a smaller initial allocation is defensible, but monitor catalysts that could justify the premium (sustained outperformance of the investment portfolio, accelerated buybacks, or material improvements in operating margins). Because the valuation methods disagree materially, use position sizing and a clearly defined target or stop policy rather than treating the current price as a clear buy.